Clinical Trial

EvE Bio and DrugBank Partner to Bring Record-Scale Pharmome-Mapping Data to the Drug-Discovery Community

Commercial sponsorship integrates EvE Bio's growing field‑defining "pharmome" map - 385,572 rigorously confirmed drug–target interactions across 159 validated targets - into…

1 month ago

Linus Health Highlights AI-Enabled Solutions Advancing Early Alzheimer’s Detection and Clinical Trial Readiness at CTAD 2025

BOSTON, Nov. 18, 2025 /PRNewswire/ -- Linus Health, an AI-driven brain health company pioneering early detection of cognitive impairment and…

1 month ago

MRO Accelerates Clinical Research Innovation with the Acquisition of Clinetic

NORRISTOWN, Pa., Nov. 18, 2025 /PRNewswire/ -- MRO announces the acquisition of Clinetic, a leading recruitment management platform designed to help healthcare…

1 month ago

Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Vancouver, Canada, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…

1 month ago

AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program

OCALA, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today provided a…

1 month ago

Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer

More than 20 years of financial and operational leadership in biopharma, including $170M+ in capital raised, global commercialization experience, and…

1 month ago

Tivic Secures Barda Meeting for Entolimod(TM) for Acute Radiation Syndrome

Meeting with Radiological and Nuclear Medical Countermeasures Program FREMONT, CA / ACCESS Newswire / November 18, 2025 / Tivic Health®…

1 month ago

NetraMark Signs Four New Contracts With a Leading Global Pharmaceutical Company To Enhance Clinical Trial Insights

TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a…

1 month ago

OKYO Pharma to Present at OIS XV in San Diego

LONDON and NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is…

1 month ago

Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer

RAD 402 is a humanized IgG1 internalized by prostate cells, binding KLK3 with high affinity Tb-161 antitumor activity driven by…

1 month ago